Sen. Blumenthal: Mylan DOJ Settlement a 'Sweetheart' Deal

The transcript discusses the Department of Justice's $465 million settlement with Mylan over EpiPen misclassification and overcharging issues. Senator Richard Blumenthal calls for further investigation, citing inadequate accountability and potential fraud. The discussion highlights the importance of EpiPens, the impact of misclassification on rebates, and the need for government intervention in drug pricing. Concerns are raised about the quick settlement and its implications for taxpayers and the broader pharmaceutical industry.

What was the amount of the settlement that Mylan agreed to pay?

What did Senator Richard Blumenthal call for in relation to the settlement?

Why does the speaker believe the settlement amount is inadequate?

What potential wrongdoing is suggested regarding Mylan's classification of the EpiPen?

How has the price of EpiPens changed according to the text?

What is the speaker's stance on the government's role in ensuring the availability of EpiPens?

What does the speaker suggest should happen to individuals involved in potential wrongdoing?